Olmesartan medoxomil vs. Telmisartan: side effect and effectiveness comparison (a real world drug study)
Summary:
We compare the side effects and drug effectiveness of Olmesartan medoxomil and Telmisartan. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 95,973 people who take Olmesartan medoxomil and Telmisartan, and is updated regularly.
What is Olmesartan medoxomil?
Olmesartan medoxomil has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 15,240 Olmesartan medoxomil users. Check the latest studies of Olmesartan medoxomil.
What is Telmisartan?
Telmisartan has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 9,163 Telmisartan users. Check the latest studies of Telmisartan.
95,973 people who take Olmesartan medoxomil and Telmisartan are studied.
Drugs being compared in this study:
- Olmesartan Medoxomil (olmesartan medoxomil)
- Telmisartan (telmisartan)
Most common side effects of the drugs, overall:
Most common side effects of the drugs, in long term (1+ years) use:
Drug effectiveness:
Olmesartan Medoxomil:
- not at all: 1.33 %
- somewhat: 13.15 %
- moderate: 32.0 %
- high: 37.72 %
- very high: 15.81 %
Telmisartan:
- not at all: 1.58 %
- somewhat: 11.72 %
- moderate: 37.32 %
- high: 39.12 %
- very high: 10.26 %
Want to compare Olmesartan medoxomil with Telmisartan?
- Personalize this study to your gender and age (0-99+)How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies
- Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
- Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .
- Kato Y, Mukai Y, Rane A, Inotsume N, Toda T, "The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study", Biological and Pharmaceutical Bulletin, 2017 Sep .
- Kim HK, Youm JB, Lee SR, Lim SE, Lee SY, Ko TH, Nilius B, Noh JH, Ko KS, Rhee BD, Kim N, "The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action", Pflügers Archiv-European Journal of Physiology, 2012 Dec .
Related studies
Alternative drugs to, pros and cons of:
- Olmesartan medoxomil (14,971 reports)
- Telmisartan (8,644 reports)
Browse all side effects of Olmesartan medoxomil:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Telmisartan:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study is based on olmesartan medoxomil and telmisartan (the active ingredients of Olmesartan medoxomil and Telmisartan, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Diclofenac cause Joint Ankylosis? - now
- Could Diclofenac cause Abdominal Pain Aggravated? - 2 seconds ago
- Drug interactions of Metoprolol Tartrate and Carbamazepine - 4 seconds ago
- Could Duragesic-100 cause Mitral Valve Incompetence? - 7 seconds ago
- Could Celebrex cause Calculus Ureteric? - 13 seconds ago
- Pulmonary Hypertension and Protein Urine Present - 13 seconds ago
- Could Wellbutrin cause Diabetic Gastroparesis? - 20 seconds ago
- Drug interactions of Ceftriaxone Sodium and Isosorbide Dinitrate - 22 seconds ago
- Could Atropine cause Diabetes? - 23 seconds ago
- Could Alcohol cause Chills? - 33 seconds ago